GD3 ganglioside is a promising therapeutic target for glioma patients.
Neuro-Oncology Advances · 01.01.2024 · 6 (1)
DOI: 10.1093/noajnl/vdae038 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology Advances, online erschienen am 19.03.2024. Verfasst von Victoria Hein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Université, CNRS, INP, Inst Neurophysiopathol, GlioME Team, Marseille, France. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma is the most frequent and aggressive primary brain tumor in adults. Currently, no curative treatment is available. Despite first-line treatment composed by the association of surgery, radiotherapy, and chemotherapy, relapse remains inevitable in a median delay of 6 to 10 months. Improving patient management and developing new therapeutic strategies are therefore a critical medical need in neuro-oncology. Gangliosides are sialic acid-containing glycosphingolipids, the most abundant in the nervous system, representing attractive therapeutic targets. The ganglioside GD3 is highly expressed in neuroectoderm-derived tumors such as melanoma and neuroblastoma, but also in gliomas. Moreover, interesting results, including our own, have reported the involvement of GD3 in the stemness of glioblastoma cells. In this review, we will first describe the characteristics of the ganglioside GD3 and its enzyme, the GD3 synthase (GD3S), including their biosynthesis and metabolism. Then, we will detail their expression and role in gliomas. Finally, we will summarize the current knowledge regarding the therapeutic development opportunities against GD3 and GD3S.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aix-Marseille Université, CNRS, INP, Inst Neurophysiopathol, GlioME Team, Marseille, France.
- Aix-Marseille Univ, Réseau Préclinique et Translationnel de Recherche en Neuro-oncologie PETRA, Plateforme PETRA"TECH" and Plateforme PE"TRANSLA," Marseille, France.
- APHM, CHU Timone, Service de Neuro-Oncologie, MarseilleFrance.
ORCID-Profile: Nathalie Baeza-Kallee, Carole Colin, Aurélie Tchoghandjian, Dominique Figarella-Branger, Emeline Tabouret
Zitieren
APA
Hein, V., Baeza-Kallee, N., Bertucci, A., Colin, C., Tchoghandjian, A., Figarella-Branger, D., & Tabouret, E. (2024). GD3 ganglioside is a promising therapeutic target for glioma patients. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae038
Vancouver
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, et al. GD3 ganglioside is a promising therapeutic target for glioma patients. Neuro-Oncology Advances. 2024;6(1). doi:10.1093/noajnl/vdae038
BibTeX
@article{Hein2024,
author = {Hein, Victoria and Baeza-Kallee, Nathalie and Bertucci, Alexandre and Colin, Carole and Tchoghandjian, Aurélie and Figarella-Branger, Dominique and Tabouret, Emeline},
title = {GD3 ganglioside is a promising therapeutic target for glioma patients},
journal = {Neuro-Oncology Advances},
year = {2024},
volume = {6},
number = {1},
doi = {10.1093/noajnl/vdae038}
}
EUVIMED